China
士泽生物医药, a promising biopharmaceutical startup founded in 2021, is dedicated to revolutionizing treatments for significant diseases lacking clinical solutions, such as Parkinson's disease. The firm employs scalable, low-cost stem cell therapies, leveraging the potential of human pluripotent stem cells capable of unlimited proliferation and multi-directional differentiation.
Under the leadership of Dr. Li Xiang, the company has established a 1600㎡ R&D center and is constructing a 3500㎡ production base. Key achievements include the successful construction of an iPS cell reprogramming and gene-editing platform and a Parkinson’s disease animal model for drug safety and efficacy evaluation.
Since its inception, 士泽生物医药 has raised over ¥100 million through multiple funding rounds led by notable investors such as Fengrui Capital, Lilly Asia Ventures, and Sequoia China. The company's most recent financing was a Series A round in April 2023, secured with the participation of Zijin Hongyun Fund and BioVenture.
Positioned as a trailblazer in China's burgeoning stem cell therapy market, 士泽生物医药 merges a strong foundation with strategic foresight, striving for breakthroughs that will profoundly impact the lives of patients worldwide.
